US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRIBECA STRATEGIC ACQUISITION CORP

9.91

+0.00500.05%

Volume:1K

Turnover:14.01K

Market Cap:190.94M

PE:-139.18

High:9.91

Open:9.91

Low:9.91

Close:9.90

52wk High:10.02

52wk Low:9.83

Shares:19.28M

Float Shares:12.97M

Volume Ratio:0.36

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0712

EPS(LYR):-0.0712

ROE:--

ROA:--

PB:-2614.55

PE(LYR):-139.18

Loading ...

Overview Company News Filings

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Press Release: Aurora Cannabis Corrects Inaccurate Statements MADE in Support of Curaleaf Holdings' Hostile BID

Press Release: Terravest Announces Renewal of Normal Course Issuer BID for ITS Common Shares

Tribeca Strategic Acquisition Net Income Falls to $243,475 in Q2 FY26

Press Release: ACT Energy Technologies Announces TSX Approval for Renewal of Normal Course Issuer BID

Press Release: Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Press Release: Akita Drilling Ltd.NORMAL Course Issuer BID

Press Release: Tourmaline Announces Renewal of Normal Course Issuer BID

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BID/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BID","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BID\",,,,,undefined,":{"symbol":"BID","market":"US","secType":"STK","nameCN":"TRIBECA STRATEGIC ACQUISITION CORP","latestPrice":9.905,"timestamp":1789653849050,"preClose":9.9,"halted":0,"volume":1414,"delay":0,"changeRate":0.0005050505050504045,"floatShares":12973000,"shares":19276700,"eps":-0.071166,"marketStatus":"Trading","change":0.005,"latestTime":"09-17 10:06:16 EDT","open":9.91,"high":9.91,"low":9.905,"amount":14009.207827999999,"amplitude":0.000505,"askPrice":9.91,"askSize":3500,"bidPrice":9.9,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.071166,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1784520000000,"exchange":"NASDAQ","adjPreClose":9.9,"volumeRatio":0.355795},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BID\",,,,,undefined,":{"symbol":"BID","floatShares":12973000,"roa":"--","roe":"--","lyrEps":-0.071166,"volumeRatio":0.355795,"shares":19276700,"dividePrice":0,"high":9.91,"amplitude":0.000505,"preClose":9.9,"low":9.905,"week52Low":9.825,"pbRate":"-2614.55","week52High":10.015,"institutionHeld":0.9362,"latestPrice":9.905,"committee":-0.75,"eps":-0.071166,"divideRate":0,"volume":1414,"delay":0,"ttmEps":-0.071166,"open":9.91,"prevYearClose":9.9,"prevWeekClose":9.94,"prevMonthClose":9.89,"prevQuarterClose":9.9,"fiveDayClose":9.94,"twentyDayClose":9.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BID\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BID\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BID\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BID\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BID","date":"2026-09-16","current":-139.111373,"percent":0.2,"low":-581.007118,"twenty":-574.622426,"median":-572.300718,"eighty":-571.139865,"high":-570.559438,"avg":-573.452254,"sd":2.642465,"marketCap":190839003},"quantilePoints":[{"date":"2026-07-24","current":-570.617481,"twenty":-572.387997,"median":-571.139865,"eighty":-570.605872,"marketCap":189508913},{"date":"2026-07-31","current":-571.139865,"twenty":-571.372035,"median":-571.139865,"eighty":-570.559438,"marketCap":189682403},{"date":"2026-08-07","current":-571.72029,"twenty":-571.72029,"median":-571.139865,"eighty":-570.594264,"marketCap":189875169},{"date":"2026-08-14","current":-574.622426,"twenty":-571.952461,"median":-571.139865,"eighty":-570.756782,"marketCap":190839003},{"date":"2026-08-21","current":-572.300718,"twenty":-572.300718,"median":-571.72029,"eighty":-571.023779,"marketCap":190067936},{"date":"2026-08-28","current":-574.622426,"twenty":-573.113316,"median":-571.72029,"eighty":-571.139865,"marketCap":190839003},{"date":"2026-09-04","current":-578.68541,"twenty":-574.041998,"median":-572.300718,"eighty":-571.139865,"marketCap":192188369},{"date":"2026-09-11","current":-576.94413,"twenty":-574.622426,"median":-572.300718,"eighty":-571.139865,"marketCap":191610069},{"date":"2026-09-16","current":-574.622426,"twenty":-574.622426,"median":-572.300718,"eighty":-571.139865,"marketCap":190839003}],"updateTime":1789653976517},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BID\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667769623","title":"Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769623","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667769623?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:01","pubTimestamp":1789416060,"startTime":"0","endTime":"0","summary":"Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3361527/0/en/sionna-therapeutics-announces-plans-to-advance-sion-451-sion-2222-dual-combination-into-phase-2a-proof-of-concept-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0630314457.HKD","VEGI","LU0345780950.USD","PK","BK4093","LU0345781412.USD","BK4181","BID","BK4585","CF","SION","BK4139","BK4218","BK4588","KBWY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715769","title":"Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715769?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:30","pubTimestamp":1787743800,"startTime":"0","endTime":"0","summary":"Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351240/0/en/trevi-therapeutics-announces-upcoming-presentations-at-the-european-respiratory-society-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","LENZ","BK4139","BID","FAS","BK4007","BK4585","RCC","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661914273","title":"Press Release: Aurora Cannabis Corrects Inaccurate Statements MADE in Support of Curaleaf Holdings' Hostile BID","url":"https://stock-news.laohu8.com/highlight/detail?id=2661914273","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661914273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:05","pubTimestamp":1787569500,"startTime":"0","endTime":"0","summary":"-- Curaleaf's self-serving portrayal of our business is an attempt to. acquire Aurora's world class EU-GMP manufacturing facilities and global. medical cannabis footprint at the lowest price possible. -- Aurora's international strategy is working; net revenue is up 17%YOY. -- Contrary to Curaleaf's inaccurate statements, Aurora's high margin German. business is growing and continues to be a key driver of Aurora's. -- Shareholders are advised to TAKE NO ACTION pending formal recommendation. from the Board and Special Committee. Offer remains open for at least 105. -- Questions about the Offer or would like to stay informed?Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MJ","BK4588","BID","MSOS","03160","BK4007","BK4604","YOLO","BK4585","BK4099","CURLF","CNBS","BK4555","MSOX","WEED","BK4557","R","TM","BK4232","TOKE","BK4022","ACB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660475362","title":"Press Release: Terravest Announces Renewal of Normal Course Issuer BID for ITS Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660475362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660475362?lang=en_us&edition=fundamental","pubTime":"2026-08-20 05:00","pubTimestamp":1787173200,"startTime":"0","endTime":"0","summary":"VEGREVILLE, AB, Aug. 19, 2026 /CNW/ -- TerraVest Industries Inc. (\"TerraVest\" or the \"Corporation\") (TSX: TVK) announced today that it has received the approval of the Toronto Stock Exchange (the \"TSX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315121","title":"Tribeca Strategic Acquisition Net Income Falls to $243,475 in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315121","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:43","pubTimestamp":1786740206,"startTime":"0","endTime":"0","summary":"Tribeca Strategic Acquisition net income falls to $243,475 in Q2 FY26Tribeca Strategic Acquisition posted net income of USD 243,475 for the three months ended June 30, 2026.Interest income on Trust Ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL7CD5WD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658117946","title":"Press Release: ACT Energy Technologies Announces TSX Approval for Renewal of Normal Course Issuer BID","url":"https://stock-news.laohu8.com/highlight/detail?id=2658117946","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658117946?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:30","pubTimestamp":1786483800,"startTime":"0","endTime":"0","summary":"CALGARY, AB, Aug. 11, 2026 /CNW/ -- ACT Energy Technologies Ltd. (TSX: ACX) (\"ACT\", the \"Company\", \"we\", \"us\" or \"our\") is pleased to announce that the Toronto Stock Exchange (\"TSX\") has accepted and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BID","BK4229","ACT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997893","title":"Press Release: Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997893","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997893?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":"Hair Loss: In July 2026, Veradermics announced positive topline results. from its open-label Phase 2 clinical trial  evaluating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2065732104.USD","MANE","BID","BK4007","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637236","title":"Press Release: Akita Drilling Ltd.NORMAL Course Issuer BID","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637236?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:00","pubTimestamp":1786050000,"startTime":"0","endTime":"0","summary":"CALGARY, AB, Aug. 6, 2026 /CNW/ -- AKITA Drilling Ltd. (TSX: AKT) The Toronto Stock Exchange (the \"TSX\" or the \"Exchange\") has accepted Akita Drilling Ltd.'s (the \"Corporation\") Notice of Intention to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","BID","AKTAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364206","title":"Press Release: Tourmaline Announces Renewal of Normal Course Issuer BID","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364206?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"CALGARY, AB, Aug. 6, 2026 /CNW/ -- Tourmaline Oil Corp. (TSX: TOU) (\"Tourmaline\" or the \"Company\") is pleased to announce that the Toronto Stock Exchange (the \"TSX\") has approved the renewal of Tourma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4527","MA","IE00BKDWB100.SGD","MPLT","FDFF","LATR","LU0823417653.USD","LU0823434583.USD","LU0823421333.USD","LU0642271901.SGD","LU2092937148.SGD","LU0107464264.USD","XLF","LU2506951958.HKD","BK4139","IE000WAW04H5.SGD","LU0096362180.USD","LU1983260115.SGD","VFH","IPAY","LU2360107671.USD","LU0708995401.HKD","IYG","ASD","LU1280957306.USD","LU1732800096.USD","BK4533","LU1712237335.SGD","SG9999003800.SGD","IE00B4JS1V06.HKD","LU2077746001.SGD","LU1861217088.USD","BK4585","LU2092627202.USD","LU2420271590.USD","STBQ","FNCL","BID","LU2168563687.JPY","LU0056508442.USD","LU0210533765.USD","LU1718418525.SGD","LU0061475181.USD","LU0557290698.USD","LU0823421416.USD","LU2168564149.EUR","LU1815333072.USD","LU1868836914.USD","UYG","LU1316542783.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}